BioAtla, Inc

BioAtla, Inc (NASDAQ: BCAB) is a clinical-stage biopharma company dedicated to advancing antibody-based therapies for solid tumor cancers. Its pipeline includes several investigational candidates such as Mecbotamab vedotin (BA3011), Ozuriftabmab vedotin (BA3021), Evalstotug (BA3071), and BA3182.

Positive Growth Aspects

• Encouraging Clinical Progress with BA3182: BioAtla demonstrated meaningful progress across its clinical portfolio in Q2 2025. Its lead asset, BA3182 (CAB-EpCAM x CAB-CD3 bispecific TCE), continues to show encouraging results in heavily pretreated patients, with objective tumor reductions observed across multiple cancer types, including pancreatic, colorectal, breast, cholangiocarcinoma, and NSCLC. Notably, two colorectal cancer patients achieved prolonged progression-free intervals of 11 and 16 months, while all patients in the 0.6 mg cohort maintained stable disease. A Phase 1 data readout remains on track for the second half of 2025, with cohort expansion data expected in the first half of 2026.
• Strong Results for Ozuriftamab Vedotin (Oz-V): Ozuriftamab vedotin (Oz-V), BioAtla’s Fast Track–designated ROR2-targeting ADC, continues to produce compelling efficacy in HPV+ oropharyngeal squamous cell carcinoma (OPSCC). The trial reported an objective response rate (ORR) of 45% and a disease control rate of 100%, outcomes that significantly outperform the historical benchmarks of ORR 3.4% and median overall survival of 4.4 months in comparable patient populations. With a planned FDA meeting in Q3 2025, Oz-V is positioned as a potential candidate for accelerated approval, underscoring the company’s progress toward developing differentiated oncology therapeutics.
• Advancement of Strategic Partnerships: Management highlighted ongoing partnering discussions, with at least one transaction expected to close in 2025. A partnership at the term-sheet stage is underway, reflecting external validation of the CAB platform and BioAtla’s oncology assets. These collaborations are expected to support continued clinical development and reduce financial pressure.
• Enhanced Visibility Through Scientific Engagement: BioAtla’s strong presence at leading oncology conferences (ASCO, ESMO, AACR, PEGS) has increased visibility within the scientific and investment community. The breadth of presentations across multiple forums reinforces its position as a recognized innovator in conditionally active biologics and strengthens engagement with key stakeholders, including clinicians, regulators, and potential partners.

Growth Challenges

• Financial Strain and Cash Burn Concerns: Despite clinical progress, BioAtla faces significant financial headwinds. The company ended Q2 2025 with just USD 18.2 million in cash, a sharp decline from USD 49.0 million at the end of 2024, reflecting a sustained cash burn. While quarterly operating cash outflows improved year-over-year—from USD 50.0 million in 1H 2024 to USD 30.4 million in 1H 2025—current resources may be insufficient to fully support upcoming pivotal trials without fresh funding or partnership support.
• Expense Reductions Yet Persistent Losses: The company continues to implement cost-control measures, including workforce reductions and program prioritization. R&D expenses decreased to USD 13.7 million from USD 16.2 million in Q2 2024, and G&A expenses dropped to USD 5.0 million from USD 5.8 million. However, BioAtla still reported a net loss of USD 18.7 million in Q2, underscoring persistent financial strain. Unless near-term partnerships or milestone payments materialize, the company risks liquidity challenges in 2026.
• Risks from Early-Stage Pipeline Development: While BioAtla’s assets have shown promising early clinical results, they remain in relatively early phases of development, with pivotal Phase 3 trials yet to commence. Delays in achieving regulatory milestones or setbacks in ongoing studies could jeopardize investor confidence and extend cash runway pressures.
• Dependence on Partnerships for Sustainability: Reliance on partnership deals to sustain operations introduces uncertainty, as these discussions may not always close on schedule or at favorable terms. Given the competitive oncology landscape, BioAtla must demonstrate not only differentiated efficacy but also the ability to execute efficiently. The upcoming FDA discussions for Oz-V and the Phase 1 BA3182 data readout in 2H 2025 represent critical inflection points that will shape the company’s trajectory.

Technical Observation (on the daily chart):

BioAtla Inc. shows a sharp decline in late 2024, followed by months of sideways consolidation until a strong rally in September 2025 pushed the stock above USD 1.00. The price has since pulled back to USD 0.58, sitting just below the 20-day MA (USD 0.60) and above the 50-day MA (USD 0.46). RSI at ~41 signals cooling momentum after overbought levels.

BioAtla balancing encouraging clinical progress with financial headwinds. On the positive side, lead programs BA3182 and Ozuriftamab vedotin are demonstrating strong early efficacy signals, with Oz-V already showing outcomes far superior to standard of care and positioned for potential accelerated approval. The company is also advancing partnership discussions, which could provide much-needed external validation and financial support, while its visibility at major oncology conferences reinforces its scientific credibility. However, challenges remain with a rapidly declining cash balance of just USD 18.2 million, persistent net losses, and reliance on yet-to-be-finalized collaborations to sustain operations. Moreover, its pipeline remains early stage, leaving execution and regulatory timelines as key risks. Overall, BioAtla offers significant upside potential if clinical and partnership milestones materialize, but it faces material financial and execution-related uncertainties in the near term.

As per the above-mentioned price action, recent key business and financial updates, momentum in the stock over the last month, and technical indicators analysis, a ‘Watch’ rating has been given to BioAtla, Inc (NASDAQ: BCAB) at the current market price of USD 0.58 as of September 24,2025 at 7:45 am PDT. 

Individuals can evaluate the stock based on the support and resistance levels provided in the report in case of keen interest taking into consideration the risk-reward scenario. 

Markets are trading in a highly volatile zone currently due to certain macro-economic issues and prevailing geopolitical tensions. Therefore, it is prudent to follow a cautious approach while investing.

Related Risk: This report may be looked at from a high-risk perspective and a recommendation is provided for a short duration. This report is solely based on technical parameters, and the fundamental performance of the stocks has not been considered in the decision-making process. Other factors which could impact the stock prices include market risks, regulatory risks, interest rates risks, currency risks, social and political instability risks etc. 

Note 1: Past performance is not a reliable indicator of future performance.

Note 2: The reference date for all price data, currency, technical indicators, support, and resistance level is September 24,2025. The reference data in this report has been partly sourced from REFINITIV.

Note 3: Investment decisions should be made depending on an individual's appetite for upside potential, risks, holding duration, and any previous holdings. An 'Exit' from the stock can be considered if the Target Price mentioned as per the Valuation and or the technical levels provided has been achieved and is subject to the factors discussed above.

Note 4: Target Price refers to a price level that the stock is expected to reach as per the relative valuation method and or technical analysis taking into consideration both short-term and long-term scenarios.

Note 5: ‘Kalkine reports are prepared based on the stock prices captured either from the New York Stock Exchange (NYSE), NASDAQ Capital Markets (NASDAQ), and or REFINITIV. Typically, all sources (NYSE, NASDAQ, or REFINITIV) may reflect stock prices with a delay which could be a lag of 15-20 minutes. There can be no assurance that future results or events will be consistent with the information provided in the report. The information is subject to change without any prior notice.